221 CRESCENT ST., WALTHAM, MA
Material disclosure
Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
Apogee Therapeutics Enters IL-31R Antibody Discovery Agreement with Paragon
Voting Agreement Among Stockholders
Election Results from Apogee Therapeutics 2026 Annual Meeting
Investor Presentation
Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Merger Proxy Statement
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
PREM14A
S-1MEF